Update your tester profile Login
  • Study 1400: Healthy, Sexually Active Male and Female Participants

    Research Purpose:  Study 1400

    The effect of the study drug on sexual functioning (i.e. frequency of sexual activity, thoughts, arousal, physical response etc.) when given to healthy sexually active adults.

    • The effect of the study drug compared to the effect of placebo and paroxetine (an FDA approved comparator drug) on sexual functioning

     

    Screening Qualifications: Participants must meet the following minimum criteria in order to qualify for a screening appointment:

    • Males and Females allowed. Age 18-45 years
    • Body Mass Index (BMI) between 18 and 35
    • No tobacco or nicotine use in the previous 12 months
    • Must be healthy; not being evaluated or treated for any medical conditions
    • Must not require regular use of prescription medications, non-prescription medications, or vitamins
    • Must test negative for drugs of abuse.  Must have no history of drug or alcohol abuse within the previous 5 years.
    • Must be sexually active:  engaging in sexual activity at least 2 times per week on average over the past 3 months.
    • Cannot have a diagnosis of disorders related to sexual functioning including but not limited to erectile dysfunction, premature ejaculation, or any surgeries or medical procedures on genital/reproductive organs
    • Must be able and willing to discuss sexual activity/functioning with Prism staff and fill out questionnaires related to sexual activity/functioning
    • Must be able and willing to take daily, at-home dosing of the study drug

     

    Study Time Commitment: For participants who qualify based on screening evaluation, study participation will last for approximately 6 weeks.  During that time, participants will visit Prism Clinical Research for approximately 7 outpatient appointments.  Participants will also take daily, at-home doses of the study drug and will keep an outpatient study diary.

     

    Compensation: Up to $1575.00 for study participation time.

  • Study 1405: Healthy Male and Female Participants

    Research Purpose:  Study 1405 is designed to evaluate the interaction of an investigational drug being developed for the treatment of human rhinovirus (cause of common cold) has on a FDA approved sedative, midazolam (Versed®).  the investigational drug will be given orally to healthy participants for seven consecutive days in the form of a capsule.  The total daily dose will be the same, but may be given either once or twice a day.  The FDA approved sedative will be given to participants orally, as a syrup. Participants will receive 4 total doses of the sedative. The following will be evaluated:

    • How the investigational drug impacts the blood levels of the FDA approved sedative
    • How midazolam (Versed®) impacts the blood levels of the investigational drug
    • the safety/tolerability of the investigational drug

     

    Minimum Screening Qualifications:

    Males

    Men are allowed to participate

    Females

    Women are allowed to participate only if they are not pregnant or lactating

    Age

    18-55 years

    Body Mass Index (BMI)

    18 and 30

    Weight

    Must weigh greater or equal to 110 pounds

    Tobacco/Nicotine Use

    • Must not use of tobacco/nicotine products more than 5 times/day in the 90 days before the study. 
    • Must be able and willing to abstain from tobacco/nicotine use 14 days before the start of the study until the final study visit. 

    Drug Testing

    Must test negative for drugs of abuse. 

    Substance Abuse History

    No history of drug or alcohol abuse within 2 years before the start of the study

    Health History

    Must be healthy; not being evaluated or treated for any medical conditions unless otherwise approved on a case by case basis by the study doctor

    Restricted Medications

    • No chronic use of any prescription medications not listed below in the 90 days prior to the start of the study through the final study visit
    • No over-the-counter medications, supplements, or vitamins 7 days prior to the start of the stud through the final study visit.

    Allowed Medications

    • Prescription hormonal birth control is allowed

     

    Study Time Commitment:

    For participants who qualify based on screening evaluation, study participation will last for approximately 16 days, beginning with the second study visit. 

     

    In-house Stays

    Participants will stay at Prism Clinical Research several times times. 

    • Three of the inpatient stays will last 1 and 1/2 days each
    • One of the inpatient stays will last 4 and 1/2 days

    Office Visits

    There will also be 4 brief morning visit for all participants, and on brief evening visit for participants dosing twice a day. 

     

    Compensation: For study participation time: Up to $2275.00 for once a day dosing; or $2350 for twice a day dosing.

  • Study 1401 Cohort 1: Healthy Male and Female Particpants

    Research Purpose: Study 1401 is designed to evaluate an investigational drug being developed for the treatment of pain management. Two pill formulations of the investigational drug will be given to healthy adults.  The following will be evaluated:

    • How much of the investigational drug gets into the blood when it’s given after eating food
    • How quickly the investigational drug gets into the blood and is eliminated from the body when it’s given after eating food
    • The safety/tolerability of the investigational drug

     

    Minimum Screening Qualifications:

    Males

    Men are allowed to participate.

    Females

    Women are allowed to participate. 

    Age

    18-55 years

    Body Mass Index (BMI)

    17.5 and 30.5

    Weight

    Must weigh more than 110 pounds

    Tobacco/Nicotine Use

    Must be able and willing to abstain from tobacco or nicotine containing products during all inpatient stays

    Drug Testing

    Must test negative for drugs of abuse. 

    Alcohol/Drug Abuse History

    No history of drug or alcohol abuse

    Health History

    Must be healthy; not being evaluated or treated for any medical conditions unless otherwise approved on a case by case basis by the study doctor

    Restricted Medications

    No required regular use of any prescription medications, non-prescription medications, or vitamins that are not listed below.

    Allowed Medications

    Prescription hormonal birth control use is permitted

    Dietary Requirements

    Must be able and willing to eat/drink the following: eggs, pork products, gluten, dairy, potatoes, and fruit (strawberries, grapes)

     

    Study Time Commitment: For participants who qualify based on screening evaluation, study participation will last for approximately 3 weeks. 

    Inpatient Stays

    • Participants will stay at Prism Clinical Research 3 times. 
    • Inpatient stays will last approximately 72 hours (three overnights

    Outpatient Visits

    • There are no scheduled outpatient visits in this study. 

     

    Compensation: Up to $2625.00

  • Study 1314-Participants with Type 2 Diabetes

    RESEARCH PURPOSE:  To study the safety, absorption, and elimination of a new investigational delayed release diabetes medication compared to an FDA approved version.  Also to determine how the medication affects the body in participants with Type 2 diabetes with normal kidney function and in participants with Type 2 diabetes and low kidney function.

     

    BASIC PARTICIPANT QUALIFICATIONS:

    • Men and Women with Type 2 Diabetes
    • Men and Women with Type 2 Diabetes and low kidney function
    • Aged 18-80 years old
    • BMI between 18--40
    • Stable and controlled medical conditions
    • All medicines will be reviewed before qualification is determined
    • Able and willing to eat/drink or avoid study specific foods/beverages

    STUDY LENGTH: One initial screening visit to determine eligibility.  A baseline overnight stay to confirm eligibility followed by 3 treatment periods each consisting of 4 days, 3 nights inpatient and 2 outpatient visits.  Each treatment period is seperated by 2 to 5 days.

     

    COMPENSATION: Up to $2,950

              

                         For more information about this research, please contact:

                         Kevin Fitzgerald: 651-724-5046 or prismresearchinc.com

  • Study 1404: Healthy Male and Female (of Non-Child Bearing Potential) Particpants

    Research Purpose:  Study 1404 is designed to evaluate two different formulations of an investigational drug being developed for the treatment of human rhinovirus. The investigational drug will be given orally to healthy participants two times: once in the form of a tablet and once in the form of a capsule. The following will be evaluated:

    • How much of the investigational drug gets into the blood when it is given as the tablet formulation verses the capsule formulation
    • The safety/tolerability of the investigational drug

    Minimum Screening Qualifications:

    Males

    Men are allowed to participate

    Females

    Women are allowed to participate only if they are postmenopausal or surgically sterilized by hysterectomy, tubal ligation, or bilateral oophorectomy

    Age

    18-55 years

    Body Mass Index (BMI)

    18 and 30

    Weight

    Must weigh greater or equal to 110 pounds

    Tobacco/Nicotine Use

    • Must not use of tobacco/nicotine products more than 5 times/day in the 90 days before the study. 
    • Must be able and willing to abstain from tobacco/nicotine use 14 days before the start of the study until the final study visit. 

    Drug Testing

    Must test negative for drugs of abuse. 

    Substance Abuse History

    No history of drug or alcohol abuse within 2 years before the start of the study

    Health History

    Must be healthy; not being evaluated or treated for any medical conditions unless otherwise approved on a case by case basis by the study doctor

    Restricted Medications

    • No chronic use of any prescription medications in the 90 days prior to the start of the study through the final study visit
    • No over-the-counter medications, supplements, or vitamins 7 days prior to the start of the stud through the final study visit.

    Study Time Commitment: For participants who qualify based on screening evaluation, study participation will last for approximately 2 weeks. 

    In-house Stays

    Participants will stay at Prism Clinical Research two times. 

    • Both in-house stays will last 2 ½ days (2 overnights)
    • There will be a 6 day washout period between the two in-house stays

    Study Visits

    The second inpatient stay is followed by one brief Study Visit 5 days later.

     

    Compensation: Up to $1270.00 for study particpation time.

  • Study 1317-Participants with varying degrees of kidney function

    RESEARCH PURPOSE:  To study the safety, absorption, and elimination of an investigational anticoagulant medication in people with reduced kidney function.

    BASIC PARTICIPANT QUALIFICATIONS:

    • Males and females 18-75 years old with less then normal kidney function but otherwise healthy and demographically matched healthy participants.
    • Cannot weigh more then 220 pounds.
    • Must test negative for HIV, Hepatitis B and C.
    • Cannot currently be using anticoagulants like Coumadin, warfarin, Heparin, etc.
    • Must have no significant history of blood or blood clotting disease or disorders.
    • Medications must be stable for 30 days prior to study start.

    STUDY LENGTH: One initial screening visit to determine study eligibility. One 4 night inpatient stay at the clinical research unit followed by 3 brief outpatient visits ( admit day -1, discharge day 4, visits days 5, 6 & 28)

    COMPENSATION: Up to $1500.00

     

     

     

Where hope, science & understanding meet.

From the aspirin on the shelves of your local drugstore, to the insulin prescribed by a doctor, to the pacemaker keeping someone’s heart on track – all have been subject to clinical trials, and integral part of the Food and Drug Administration (FDA) approval process.

A critical step in an important process

Drugs and medical devices undergo years of laboratory testing before they reach the clinical trial phase. Researchers must acquire approval from the FDA for approval to continue research and testing in humans. Clinical trials are essential to measure the efficacy and safety of drugs before they are available for widespread use.

Changing lives, every day.

The impact of clinical trials are seen in our everyday lives, in the confidence with which we can take over-the-counter drugs – or in the life-saving benefits of a breakthrough medication for a victim of Leukemia.

Public Health and Safety

Prior to the development of the FDA’s rigorous and highly regulated method, consumers had to rely upon the anecdotal observation of physicians or spurious claims of pharmacists. In 1906, in order to protect public health and safety, the fledgling FDA passed the first regulatory drug act – the Pure Food and Drug Act.

In 1938, the enactment of the U.S. Food, Drug, and Cosmetic Act subjected new drugs to pre-market safety evaluation for the first time, thus enabling FDA regulators to review both pre-clinical and clinical test results, giving them the authority to block the marketing of a new drug formally or delay it by requiring additional data.

Alongside the evolving standards of drug regulations, closer regulation of the clinical trial process. The resulting process today is designed to protect the safety of study participants, promote the development of lifesaving drugs, and keep public health and safety at the center of medical advancement. In the century since the first drug act, the research and medical community in cooperation with the FDA, have developed the foremost institutional authority for conducting and evaluating controlled clinical drug trials.

Doing the right thing

Know that you’ve done your part to help make important medications available to those who need them. If you have a friend or family member who relies on a medication to treat a chronic disease or illness, they have benefited from the work of a clinical trial, and a volunteer like you who gave their time and effort to aid in the approval process.

Fair compensation for your time

You’ll be compensated based on the time you spend as a study participant.

Medical exam & monitoring

As a study participant, you’ll likely receive a full medical examination and testing for a variety of conditions. In some cases volunteers might have access to treatments or medicines before they are available to the general population.

Changing lives, advancing science, furthering the reach of medicine.

Prism Clinical Research provides, FDA approved, investigational pharmaceutical and medical device testing services on behalf of drug and device manufacturers, academic and private physicians as well as other researchers across Minnesota.

Icon 05

At Prism, we are committed to the advancement of medical knowledge and the health of our community. We have been conducting Phase I clinical trials since 2005, helping many important drugs reach FDA approval. Prism is a locally owned and operated, independent facility in the heart of the Minneapolis/St. Paul metropolitan area. 

Whether you are here because you are interested in participating in a clinical trial, or you’re searching for a trusted partner to conduct a study on your behalf, our hope is that you find the information you need and the confidence to take the next step. 

With your help, we can make a difference.


Learn what Prism Volunteers are saying:

Volunteer Large 13

"I am VERY pleased with Prism Research. I enjoy the studies and the staff is always friendly and they all make you feel as comfortable as possible. The study compensation program is very good as well! Thank you."

  • Volunteers 08

    “Concerned enough to ask questions. I enjoy visiting with the staff. I look forward to future studies and may qualify to participate in.”

  • Volunteers 05

    “Overall you do a great job! Your staff is very friendly and accommodating. Your facility is very comfortable. Thanks!”

  • Volunteers 06

    “Staff was courteous and well informed of the nature of the study and all of the requirements that went with it.”

  • Volunteers 07

     “Overall my experiences at Prism have been very positive and directly linked to the Staff - their demeanor, humor and professional approach.”


Please provide us with your contact information (below) and will get back to you as soon as possible.

If you have a general question, check Volunteer FAQ for an answer. If you're unsure of who to contact, please visit the Contact Us page.

Cancel